Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.

Radiographic monitoring of posttreatment glioblastoma is important for clinical trials and determining next steps in management. Evaluation for tumor progression is confounded by the presence of treatment-related radiographic changes, making a definitive determination less straight-forward. The purpose of this article was to describe imaging tools available for assessing treatment response in glioblastoma, as well as to highlight the definitions, pathophysiology, and imaging features typical of true progression, pseudoprogression, pseudoresponse, and radiation necrosis.

• Publication year

  2019

• Venue

  The Radiologic clinics of North America

• Publication date

  2019-08-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.rcl.2019.07.003PMID 31582045
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.

  2019cited by this paper
• Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686

  2018cited by this paper
• Multiparametric MRI as a potential surrogate endpoint for decision-making in early treatment response following concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma: a systematic review and meta-analysis

  2018cited by this paper
• Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma☆

  2018cited by this paper
• Glioma imaging in Europe: A survey of 220 centres and recommendations for best clinical practice

  2018cited by this paper
• 11C–MET PET/MRI for detection of recurrent glioma

  2018cited by this paper
• CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.

  2018cited by this paper
• Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas

  2018cited by this paper
• Management-Based Structured Reporting of Posttreatment Glioma Response With the Brain Tumor Reporting and Data System.

  2018cited by this paper
• Perfusion MRI in treatment evaluation of glioblastomas: Clinical relevance of current and future techniques

  2018cited by this paper
• Magnetic Resonance Spectroscopy, Positron Emission Tomography and Radiogenomics—Relevance to Glioma

  2018cited by this paper
• Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide

  2018cited by this paper
• Association of 1p/19q Codeletion and Radiation Necrosis in Adult Cranial Gliomas After Proton or Photon Therapy.

  2018cited by this paper
• Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma

  2017cited by this paper
• Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma

  2017cited by this paper
• Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps

  2017cited by this paper
• MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives

  2017cited by this paper
• MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis

  2017cited by this paper
• Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials

  2017cited by this paper
• New Directions in Anti-Angiogenic Therapy for Glioblastoma

  2017cited by this paper
• Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial

  2017cited by this paper
• Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials

  2017cited by this paper
• Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis

  2017cited by this paper
• Advanced MRI Techniques in the Monitoring of Treatment of Gliomas

  2017cited by this paper
• Visual inspection of MR relative cerebral blood volume maps has limited value for distinguishing progression from pseudoprogression in glioblastoma multiforme patients.

  2017cited by this paper
• Facing pseudoprogression after radiotherapy in low grade gliomas

  2017cited by this paper
• Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation

  2016cited by this paper
• Multicenter Survey of Current Practice Patterns in Perfusion MRI in Neuroradiology: Why, When, and How Is It Performed?

  2016cited by this paper
• Advanced MRI increases the diagnostic accuracy of recurrent glioblastoma: Single institution thresholds and validation of MR spectroscopy and diffusion weighted MR imaging

  2016cited by this paper
• Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma

  2016cited by this paper
• Survival in glioblastoma: a review on the impact of treatment modalities

  2016cited by this paper
• IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.

  2016cited by this paper
• Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab

  2016cited by this paper
• Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation

  2016cited by this paper
• Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.

  2016cited by this paper
• Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy

  2016cited by this paper
• Posttreatment Evaluation of Brain Gliomas.

  2016cited by this paper
• The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic review and meta-analysis

  2016cited by this paper
• Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI

  2015cited by this paper
• Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

  2015cited by this paper
• Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value

  2015cited by this paper
• MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

  2015cited by this paper
• Arterial spin labeling MRI: Clinical applications in the brain

  2015cited by this paper
• Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy.

  2015cited by this paper
• Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET

  2015cited by this paper
• Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression

  2015cited by this paper
• Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence

  2015cited by this paper
• Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options

  2015cited by this paper
• The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping

  2015cited by this paper
• Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate

  2015cited by this paper
• From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?

  2015cited by this paper
• Current challenges in designing GBM trials for immunotherapy

  2015cited by this paper
• Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy – Detecting Illusive Disease, Defining Response

  2015cited by this paper
• Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.

  2015cited by this paper
• What next for newly diagnosed glioblastoma?

  2015cited by this paper
• Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma

  2015cited by this paper
• The role of imaging in the management of progressive glioblastoma

  2014cited by this paper
• Recurrent glioblastoma multiforme versus radiation injury: a multiparametric 3-T MR approach

  2014cited by this paper
• Comparison of diffusion tensor, dynamic susceptibility contrast MRI and (99m)Tc-Tetrofosmin brain SPECT for the detection of recurrent high-grade glioma.

  2014cited by this paper
• Cancer incidence and mortality in the Czech Republic.

  2014cited by this paper
• Antiangiogenic therapy for high-grade glioma.

  2014cited by this paper
• Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.

  2014cited by this paper
• Differentiation of Tumor Progression from Pseudoprogression in Patients with Posttreatment Glioblastoma Using Multiparametric Histogram Analysis

  2014cited by this paper
• Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: a systematic review and meta-analysis.

  2014cited by this paper
• Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy

  2014cited by this paper
• Diagnostic Accuracy of PET for Recurrent Glioma Diagnosis: A Meta-Analysis

  2013cited by this paper
• Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations.

  2013cited by this paper
• Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis

  2013cited by this paper
• Recurrent glioblastoma: optimum area under the curve method derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.

  2013cited by this paper
• MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high‐grade gliomas

  2013cited by this paper
• Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease.

  2013cited by this paper
• Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression

  2013cited by this paper
• Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.

  2013cited by this paper
• Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging

  2013cited by this paper
• IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy

  2013cited by this paper
• Prediction of Pseudoprogression in Patients with Glioblastomas Using the Initial and Final Area Under the Curves Ratio Derived from Dynamic Contrast-Enhanced T1-Weighted Perfusion MR Imaging

  2013cited by this paper
• Computerized MRS voxel registration and partial volume effects in single voxel 1H-MRS.

  2013cited by this paper
• True Progression versus Pseudoprogression in the Treatment of Glioblastomas: A Comparison Study of Normalized Cerebral Blood Volume and Apparent Diffusion Coefficient by Histogram Analysis

  2013cited by this paper
• Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-18F-Fluorethyl)-L-Tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging

  2013cited by this paper
• The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates

  2013cited by this paper
• Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.

  2012cited by this paper
• Brain perfusion imaging: How does it work and what should I use?

  2012cited by this paper
• Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.

  2012cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

  2012cited by this paper
• Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival

  2012cited by this paper
• Performance of 18F-Fluoro-Ethyl-Tyrosine (18F-FET) PET for the Differential Diagnosis of Primary Brain Tumor: A Systematic Review and Metaanalysis

  2012cited by this paper
• Diffusion-weighted MRI as a biomarker for treatment response in glioma.

  2012cited by this paper
• Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas.

  2012cited by this paper
• Magnetic Resonance Spectroscopy for Differentiating Pseudo-Progression from True Progression in GBM on Concurrent Chemoradiotherapy

  2012cited by this paper
• Distinguishing Pseudoprogression From True Progression by FLAIR Volumetric Characteristics Compared to 45 Gy Isodose Volumes in Treated Glioblastoma Patients

  2012cited by this paper
• Comparison of 18F-Fluorodeoxyglucose and 18F-Fluorothymidine PET in Differentiating Radiation Necrosis From Recurrent Glioma

  2012cited by this paper
• Comparison of F-18 FDG and C-11 Methionine PET/CT for the Evaluation of Recurrent Primary Brain Tumors

  2012cited by this paper
• Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum--use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI.

  2012cited by this paper
• Distinguishing recurrent high-grade gliomas from radiation injury: a pilot study using dynamic contrast-enhanced MR imaging.

  2011cited by this paper
• Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma

  2011cited by this paper
• MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study

  2011cited by this paper
• Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.

  2011cited by this paper
• Isolated Diffusion Restriction Precedes the Development of Enhancing Tumor in a Subset of Patients with Glioblastoma

  2011cited by this paper
• Diagnosis and treatment in neuro-oncology: an oncological perspective.

  2011cited by this paper
• ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma

  2011cited by this paper

• A Radiologist’s Guide to IDH-Wildtype Glioblastoma for Efficient Communication With Clinicians: Part II–Essential Information on Post-Treatment Imaging

  2025cites this paper
• Diagnostic value and efficacy of multimodal magnetic resonance imaging in differentiating radiation necrosis from tumor recurrence in glioblastomas

  2025cites this paper
• Pseudoprogression in Pediatric Spinal Pilocytic Astrocytoma and Myxopapillary Ependymoma after Proton Therapy: A Case Series

  2025cites this paper
• Neuroimaging endpoints for clinical trials in gliomas: the neuro-oncologist perspective.

  2025cites this paper
• Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort

  2025cites this paper
• Efficacy of Anlotinib in Treating Progressive Glioblastoma: Insights From a Single-Center Study

  2025cites this paper
• Impact of radiation fractionation on pseudoprogression in older patients with glioblastoma: a retrospective cohort study

  2025cites this paper
• Estudio de 18F-FET PET/CT para diferenciar viabilidad tumoral de radionecrosis en pacientes con gliomas de alto grado: experiencia de un centro de referencia en Medellín, Colombia

  2025cites this paper
• Evaluating circulating tumour cell enrichment techniques to establish an appropriate method for clinical application in glioblastomas

  2024cites this paper
• Low rCBV values in glioblastoma tumor progression under chemoradiotherapy

  2024influential citation
• Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas

  2024cites this paper
• “Synthetic” DSC Perfusion MRI with Adjustable Acquisition Parameters in Brain Tumors Using Dynamic Spin-and-Gradient-Echo Echoplanar Imaging

  2024cites this paper
• Neoadjuvant combination treatment with checkpoint inhibitors, chemotherapy, and BRAF/MEK inhibitors for BRAFV600E glioblastoma results in sustained response: A case report

  2024cites this paper
• Beyond conventional imaging: Advancements in MRI for glioma malignancy prediction and molecular profiling.

  2024cites this paper
• Resolving spatial response heterogeneity in glioblastoma

  2024cites this paper
• Clinical Theranostics in Recurrent Gliomas: A Review

  2024cites this paper
• Imaging and Liquid Biopsy for Distinguishing True Progression From Pseudoprogression in Gliomas, Current Advances and Challenges.

  2024cites this paper
• Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas

  2024cites this paper
• Artificial intelligence-based MRI radiomics and radiogenomics in glioma

  2024cites this paper
• Radiomic features on multiparametric MRI for differentiating pseudoprogression from recurrence in high-grade gliomas

  2024cites this paper
• Molecular Imaging of Glial Tumors: Established and Emerging Tracers

  2023cites this paper
• Extracellular-Vesicle-Based Cancer Panels Diagnose Glioblastomas with High Sensitivity and Specificity

  2023cites this paper
• Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series

  2023cites this paper
• Differentiating tumour progression from pseudoprogression in glioblastoma patients: a monoexponential, biexponential, and stretched-exponential model-based DWI study

  2023cites this paper
• RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults

  2023cites this paper
• Recapitulating the Key Advances in the Diagnosis and Prognosis of High-Grade Gliomas: Second Half of 2021 Update

  2023cites this paper
• Dialog beyond the Grave: Necrosis in the Tumor Microenvironment and Its Contribution to Tumor Growth

  2023cites this paper
• Charged particle therapy for high-grade gliomas in adults: a systematic review

  2023cites this paper
• Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study

  2023cites this paper
• Response Assessment in Brain Metastases Managed by Stereotactic Radiosurgery: A Reappraisal of the RANO-BM Criteria

  2023cites this paper
• Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI

  2023cites this paper
• Post-treatment imaging of gliomas: challenging the existing dogmas.

  2023cites this paper
• The value of arterial spin labelling (ASL) perfusion MRI in the assessment of post-treatment progression in adult glioma: A systematic review and meta-analysis.

  2023cites this paper
• Editorial: Untangling post-treatment follow up of brain tumors: the role of neuroimaging

  2023cites this paper
• Diffusion imaging could aid to differentiate between glioma progression and treatment-related abnormalities: a meta-analysis

  2022cites this paper
• TfR-T12 short peptide and pH sensitive cell transmembrane peptide modified nano-composite micelles for glioma treatment via remodeling tumor microenvironment.

  2022cites this paper
• Treatment Response and Prognosis Evaluation in High‐Grade Glioma: An Imaging Review Based on MRI

  2022influential citation
• Advanced Imaging Techniques for Newly Diagnosed and Recurrent Gliomas

  2022cites this paper
• Hemodynamic Imaging in Cerebral Diffuse Glioma—Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions

  2022cites this paper
• Hemodynamic Imaging in Cerebral Diffuse Glioma—Part A: Concept, Differential Diagnosis and Tumor Grading

  2022cites this paper
• Short TE downfield magnetic resonance spectroscopy in a mouse model of brain glioma

  2022cites this paper
• The Clinical Applications of Liquid Biopsies in Pediatric Brain Tumors: A Systematic Literature Review

  2022cites this paper
• The role of liquid biopsy in the diagnosis of glioblastoma progression

  2022cites this paper
• Glioblastoma — treatment and obstacles

  2022cites this paper
• Delayed cerebral pseudoaneurysm following surgical and combined-modality therapy for glioblastoma multiforme: illustrative case

  2022cites this paper
• The Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in the Differentiation of Pseudoprogression and Recurrence of Intracranial Gliomas

  2022cites this paper
• Radiomics for pseudoprogression prediction in high grade gliomas: added value of MR contrast agent

  2022cites this paper
• Tumor Progression and Treatment-Related Changes: Radiological Diagnosis Challenges for the Evaluation of Post Treated Glioma

  2022cites this paper
• Iatrogenic Influence on Prognosis of Radiation-Induced Contrast Enhancements in Patients with Glioma WHO 1-3 following Photon and Proton Radiotherapy.

  2022cites this paper
• A brain tumor reporting and data system to optimize imaging surveillance and prognostication in high‐grade gliomas

  2022cites this paper
• The Role of Apparent Diffusion Coefficient Values in Glioblastoma: Differentiating Tumor Progression Versus Treatment-Related Changes

  2022cites this paper
• Multimodal MRI-Based Radiomic Nomogram for the Early Differentiation of Recurrence and Pseudoprogression of High-Grade Glioma

  2022cites this paper
• Radiomic Study for Objectification of Diagnostics and Complex Treatment of Glioblastoma

  2022cites this paper
• Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas

  2022cites this paper
• Radiation necrosis of the brain

  2022cites this paper
• Undesired impact of iron supplement on MRI assessment of post-treatment glioblastoma

  2022cites this paper
• Performance of 18 F-FAPI PET/CT in assessing glioblastoma before radiotherapy: a pilot study

  2022cites this paper
• A Comparison of PET Tracers in Recurrent High-Grade Gliomas: A Systematic Review

  2022cites this paper
• Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report

  2022cites this paper
• Advancements in Neuroimaging to Unravel Biological and Molecular Features of Brain Tumors

  2021cites this paper
• Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

  2021cites this paper
• Feasibility of glioblastoma tissue response mapping with physiologic BOLD imaging using precise oxygen and carbon dioxide challenge

  2021cites this paper
• Applications of Radiomics and Radiogenomics in High-Grade Gliomas in the Era of Precision Medicine

  2021cites this paper
• A Comparison of Single- and Multiparametric MRI Models for Differentiation of Recurrent Glioblastoma from Treatment-Related Change

  2021cites this paper
• Congress of Neurological Surgeons systematic review and evidence-based guidelines for the treatment of adults with progressive glioblastoma update: introduction and methods

  2021cites this paper
• Radiology in Modern Neuro-Oncology Practice

  2021cites this paper
• Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.

  2021cites this paper
• Machine learning-based radiomic evaluation of treatment response prediction in glioblastoma.

  2021cites this paper
• Imaging Surveillance of Gliomas: Role of Basic and Advanced Imaging Techniques.

  2021cites this paper
• Multimodal assessment of disease activity in glioblastoma

  2021cites this paper
• Freiburg Neuropathology Case Conference

  2021cites this paper
• The Definition and Delineation of the Target Area of Radiotherapy Based on the Recurrence Pattern of Glioblastoma After Temozolomide Chemoradiotherapy

  2021cites this paper
• A Review of Newly Diagnosed Glioblastoma

  2021cites this paper
• Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.

  2021cites this paper
• Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.

  2020cites this paper
• The role of extracellular vesicles in the diagnosis of glioblastoma progression

  2020cites this paper
• Differentiating high-grade glioma recurrence from pseudoprogression: Comparing diffusion kurtosis imaging and diffusion tensor imaging.

  2020cites this paper
• Pseudoprogression versus true progression in glioblastoma patients: a multiapproach literature review: Part 1 - Molecular, Morphological and Clinical features.

  2020cites this paper
• Advanced magnetic resonance imaging to support clinical drug development for malignant glioma.

  2020cites this paper
• Transferrin Receptor-Targeted PEG-PLA Polymeric Micelles for Chemotherapy Against Glioblastoma Multiforme

  2020cites this paper
• Laser interstitial thermal therapy for treatment of cerebral radiation necrosis

  2020cites this paper
• Neurologic Complications of Cranial Radiation Therapy and Strategies to Prevent or Reduce Radiation Toxicity

  2020cites this paper
• Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series

  2020cites this paper
• The Role of Circulating MicroRNA in Glioblastoma Liquid Biopsy.

  2020cites this paper